• 1. N1-Coordination in palladium(II) and platinum(II) complexes with 9-methylhypoxanthine: crystal structures and theoretical calculations
  José Ruiz,Natalia Cutillas,María Dolores Villa,Gregorio López,Arturo Espinosa,Delia Bautista Dalton Trans. 2009 9637
• 2. UV-promoted radical formation, and near-IR-induced and spontaneous conformational isomerization in monomeric 9-methylguanine isolated in low-temperature Ar matrices
  Maciej J. Nowak,Igor Reva,A. J. Lopes Jesus,Leszek Lapinski,Rui Fausto Phys. Chem. Chem. Phys. 2019 21 22857
• 3. Metallocavitands: an emerging class of functional multimetallic host molecules
  Peter D. Frischmann,Mark J. MacLachlan Chem. Soc. Rev. 2013 42 871
• 4. Xanthosine 5′-monophosphate (XMP). Acid–base and metal ion-binding properties of a chameleon-like nucleotide
  Helmut Sigel,Bert P. Operschall,Rolf Griesser Chem. Soc. Rev. 2009 38 2465
• 5. Metallatriangles and metallasquares: the diversity behind structurally characterized examples and the crucial role of ligand symmetry
  Bernhard Lippert,Pablo J. Sanz Miguel Chem. Soc. Rev. 2011 40 4475

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purinones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Purinones

Introduction to 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) in Modern Chemical and Pharmaceutical Research

9-methyl-9H-purin-6-ol, identified by the Chemical Abstracts Service Number (CAS No.) 113336-00-8, is a significant heterocyclic compound that has garnered considerable attention in the fields of chemical biology and pharmaceutical development. This compound, a derivative of purine, exhibits unique structural and functional properties that make it a valuable scaffold for designing novel therapeutic agents. The presence of a methyl group at the 9-position and a hydroxyl group at the 6-position imparts distinct reactivity and biological activity, positioning it as a key intermediate in synthetic chemistry and drug discovery.

The molecular structure of 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) consists of a six-membered aromatic ring fused to a five-membered nitrogen-containing ring, typical of purine derivatives. The hydroxyl substituent at the 6-position enhances its solubility in polar solvents, facilitating its use in various biochemical assays and pharmaceutical formulations. Additionally, the methyl group at the 9-position contributes to steric stabilization, influencing its binding affinity to biological targets. These structural features have been exploited in recent research to develop compounds with potential applications in oncology, immunology, and metabolic disorders.

In recent years, 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) has been extensively studied for its role as a precursor in the synthesis of nucleoside analogs. These analogs are widely used in antiviral and anticancer therapies due to their ability to mimic natural nucleosides and interfere with viral replication or cancer cell proliferation. For instance, derivatives of this compound have shown promise in inhibiting enzymes such as kinases and polymerases, which are critical in cellular signaling pathways associated with disease progression. The hydroxyl group at the 6-position provides a reactive site for further functionalization, allowing chemists to tailor the molecule’s properties for specific therapeutic outcomes.

One of the most compelling aspects of 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) is its versatility in medicinal chemistry. Researchers have leveraged its scaffold to develop small molecules that modulate key biological processes. For example, studies have demonstrated its utility in creating inhibitors targeting Janus kinases (JAKs), which are implicated in inflammatory diseases such as rheumatoid arthritis. The ability to modify both the methyl and hydroxyl groups allows for fine-tuning of pharmacokinetic and pharmacodynamic profiles, enhancing drug efficacy while minimizing side effects.

The synthesis of 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) involves multi-step organic reactions that highlight the ingenuity of modern synthetic methodologies. Advanced techniques such as palladium-catalyzed cross-coupling reactions have enabled efficient construction of complex purine derivatives. These methods not only improve yield but also reduce environmental impact by minimizing waste generation. The growing emphasis on green chemistry has spurred innovation in the synthesis of this compound, ensuring sustainable practices align with regulatory standards and industry demands.

From a biochemical perspective, 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) serves as a critical intermediate in understanding enzyme mechanisms and developing enzyme inhibitors. Its structural similarity to natural purines allows it to interact with enzymes such as adenosine kinase and guanylate kinase, which play roles in energy metabolism and signal transduction. By studying how this compound binds to these enzymes, researchers can gain insights into disease pathogenesis and identify new therapeutic targets.

The pharmaceutical industry has recognized the potential of 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) as a building block for drug candidates. Several clinical trials are underway evaluating derivatives of this compound for their efficacy in treating various conditions. Preliminary results suggest that certain modifications can significantly enhance drug potency while maintaining safety profiles acceptable for human use. This underscores the importance of continued research into optimizing synthetic routes and exploring novel applications.

The future direction of research on 9-methyl-9H-purin-6-ol (CAS No. 113336-00-8) is likely to focus on expanding its therapeutic applications through structure-based drug design. Advances in computational chemistry and artificial intelligence are enabling researchers to predict how different modifications will affect biological activity with greater accuracy than ever before. This interdisciplinary approach promises to accelerate the discovery pipeline for new drugs derived from this versatile scaffold.

In conclusion, 9-methyl - 9 H - purin - 6 - ol( CAS NO . 1 1333 6 - 0 0 - 8 )is an important chemical compound with broad applications in pharmaceutical research . Its unique structural features , reactivity ,and potential as a precursor for nucleoside analogs make it a valuable asset for developing innovative therapies . As scientific understanding advances ,the role of this compound is expected to grow ,driving progress across multiple medical disciplines .

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)